Pharmacological ascorbate has been proposed as a potential anti-cancer agent when combined with radiation and chemotherapy. The anti-cancer effects of ascorbate are hypothesized to involve the autoxidation of ascorbate leading to increased steady-state levels of H 2 O 2 ; however, the mechanism(s) for cancer cell-selective toxicity remain unknown. The current study shows that alterations in cancer cell mitochondrial oxidative metabolism resulting in increased levels of O 2
Introduction
Intravenous pharmacological doses of ascorbate have recently re-emerged as a potential anticancer therapy with clinical trials in ovarian and pancreatic cancer subjects demonstrating tolerability with similar or reduced toxicities, relative to chemotherapy alone (Ma et al., 2014; Monti et al., 2012; Welsh et al., 2013) . Preclinical studies with ascorbate have consistently demonstrated cancer cell-selective cytotoxicity in a variety of disease sites (Du et al., 2010; Ma et al., 2014; Riordan et al., 1995) . Although the mechanism(s) of selective toxicity remain unknown, mounting evidence suggests that ascorbate toxicity is dependent on ascorbate's action as a pro-drug for hydrogen peroxide (H 2 O 2 ) generation (Chen et al., 2005 (Chen et al., , 2007 Olney et al., 2013) .
Interestingly, both H 2 O 2 toxicity and ascorbate oxidation forming H 2 O 2 are dependent upon metal ion redox chemistry (Buettner and Jurkiewicz, 1996; Du et al., 2015a; Halliwell and Gutteridge, 1990) . Furthermore, there is increasing evidence that perturbations in cancer cell oxidative metabolism result in increased steady-state levels of reactive oxygen species (ROS), including superoxide (O 2
•− ) and H 2 O 2 (Bize et al., 1980; Szatrowski and Nathan, 1991; Spitz et al., 2000; Aykin-Burns et al., 2009) , and that these species may be capable of disrupting cellular iron metabolism leading to increased labile iron pool (LIP) levels (Caltagirone et al., 2001; Ibrahim et al., 2013; Pantopoulos et al., 1997) . Indeed, many cancer cells exhibit disruptions in iron metabolism with up-regulation of several iron-uptake pathways, such as transferrin receptor (TfR), as well as down-regulation of iron export and storage pathways (Torti and Torti, 2013) .
The current study examines the role of O 2 •− -and H 2 O 2 -mediated disruptions in cancer cell iron metabolism in the selective toxicity of pharmacological ascorbate. Additionally, this study investigates the safety, tolerability, and potential efficacy of pharmacological ascorbate in combination with standard-of-care radio-chemotherapies in GBM and advanced stage NSCLC subjects.
Results

Pharmacological ascorbate selectively sensitizes NSCLC and GBM cells, as compared to normal cells, to radio-chemotherapy
The efficacy of ascorbate in pre-clinical NSCLC and GBM models was assessed using clonogenic survival assays and murine xenografts. Comparisons of the effects of ascorbate in cancer vs. normal cells in vitro were performed in identical media preparations due to the dependence of ascorbate toxicity on media constituents including pyruvate, metal ions, pH, and serum (Olney et al., 2013; Buettner, 1988; Nath et al., 1995; Clément et al., 2001; Mojić et al., 2014) . Additionally, ascorbate was dosed per cell (pmol cell −1 ), rather than by concentration, due to the dependence of ascorbate and H 2 O 2 toxicity on cell density ( Figure  S1A ) (Doskey et al., 2015; Spitz et al., 1987) . In all in vitro experiments, both dosing metrics are indicated, where available, as concentration-based metrics will be vital in future clinical applications of ascorbate. Importantly, doses utilized to demonstrate mechanistic aspects of ascorbate toxicity all fall within the range of tissue concentrations likely achieved in vivo after intravenous administration (Chen et al., 2008; Kuiper et al., 2014; Campbell et al., 2016) .
Exposure of NSCLC cells (H292 and H1299) and GBM cells (U87 and U118) to increasing doses of ascorbate demonstrated dose-dependent clonogenic cell killing ( Figures 1A, 1B) . In all cases, ascorbate was significantly more toxic to NSCLC and GBM cells, relative to normal human bronchial epithelial primary cells (HBEpCs) or normal human astrocytes (NHAs) (Figures 1A, 1B; . Furthermore, ascorbate selectively sensitized NSCLC and GBM cells, but not HBEpC or NHA, to ionizing radiation (IR) combined with chemotherapy ( Figures 1C, 1D ).
NSCLC and GBM xenograft studies demonstrated that ascorbate [4 g kg −1 intraperitoneal injection (IP), daily] combined with radio-chemotherapy significantly increased overall survival, as compared to radio-chemotherapy alone (Figures 2A, 2B) . Ascorbate treatment was well tolerated as monitored by mouse weight ( Figure 2C ), and IP delivery significantly increased ascorbate levels in the plasma, tumor, and cerebrospinal fluid in samples collected at a single time point 1 hr (therefore, not necessarily peak levels) after ascorbate administration ( Figures 2D, 2E ). These data establish the tolerability and efficacy of pharmacological ascorbate in preclinical models of NSCLC and GBM and support the existence of an intrinsic mechanism of selective ascorbate toxicity in cancer vs. normal cells.
Selective ascorbate toxicity is not dependent on dehydroascorbate (DHA) uptake
A recent report by Yun et al. (2015) suggested that the differential uptake of the 2-electron oxidation product of ascorbate, dehydroascorbic acid (DHA), by glucose transporters (GLUTs) in KRAS and BRAF mutant isogenic colorectal cells mediates the energetic crisis underlying the differential toxicity of ascorbate in cancer versus normal cells (Yun et al. 2015) . However, in the more complex genetic background used in the current report (Table  S1 ), KRAS status alone did not predict ascorbate sensitivity in NSCLC cells ( Figure S1B ).
Furthermore, competitive inhibition of GLUT transporters with 20 mM 2-deoxy-D-glucose (2-DG) did not suppress ascorbate toxicity and appeared to potentially enhance ascorbate toxicity, suggesting that uptake through GLUT-transporters does not contribute to the observed effects in these model systems ( Figure 3A ). Importantly, previous reports demonstrate inhibition of DHA uptake by 20 mM 2-DG (Rumsey et al., 1997) , and in the current model, 20 mM 2-DG inhibited total ascorbate/DHA uptake by 37% ( Figure 3B ). Furthermore, DHA was significantly less toxic as compared to ascorbate ( Figure 3C ). Taken together, these results support the conclusion that ascorbate, not DHA, is the cancer cellselective toxic species in the current model system.
Ascorbate toxicity is dependent on the intracellular reactions of H 2 O 2 and redox-active labile iron
Confirming the generality of the previously reported dependence of ascorbate toxicity on the generation of H 2 O 2 (Chen et al., 2005 (Chen et al., , 2007 Olney et al., 2013) , ascorbate toxicity in NSCLC and GBM cells was inhibited by exogenous catalase or adenoviral-mediated overexpression of catalase (AdCat) or glutathione peroxidase 1 (AdGPx1) (Figures 4A-C; Figure S2A ). As both H 2 O 2 toxicity and ascorbate oxidation to generate H 2 O 2 are dependent upon metal ion redox chemistry (Buettner and Jurkiewicz, 1996; Du et al., 2015a; Halliwell and Gutteridge, 1990) , it follows that ascorbate toxicity may be dependent on intracellular pro-oxidant metal ion chemistry, as has previously been suggested in breast and prostate cancer (Verrax and Calderon, 2009 ). Indeed, chelators that inhibit redox cycling of iron (desferrioxamine, DFO; diethylenetriamine-pentaacetic acid, DTPA) (Buettner, 1986) significantly inhibited ascorbate toxicity in both NSCLC and GBM cell lines ( Figure 4D ; Figures S2B, S2C ).
To further test the role of redox active metal ions, H292 cells were pre-incubated for 3 hr with DFO/DTPA or ethylenediaminetetraacetic acid (EDTA; known to enhance iron redox cycling) (Buettner, 1986) and washed prior to ascorbate treatment or chelator treated media was added to the cells only during ascorbate exposure, providing conditions in which the chelators were either primarily intracellular or extracellular during ascorbate exposure. Intracellular DFO/DTPA inhibited ascorbate toxicity while intracellular EDTA enhanced ascorbate toxicity relative to control or extracellular chelators ( Figure 4E ; Figure S3 ). Additionally, increasing the intracellular labile iron pool (LIP) with exogenous Fe 2+ , as ferrous ammonium sulfate (FAS), sensitized H292 NSCLC cells to ascorbate ( Figure 4F ). These results support the hypothesis that the combination of H 2 O 2 and intracellular redoxactive metal ions is necessary and sufficient for ascorbate toxicity and suggest that differences in cellular iron metabolism regulating the level of redox active iron may mediate the mechanism of cancer cell-selective ascorbate toxicity.
Disturbances in oxidative metabolism selectively sensitizes cancer cells to ascorbate through disruptions in iron metabolism
There is a growing body of literature demonstrating that disruptions in cancer cell oxidative metabolism results in increased steady-state levels of reactive oxygen species (ROS), including superoxide (O 2 •− ) and H 2 O 2 (Bize et al., 1980; Springer, 1980; Spitz et al., 2000; Aykin-Burns et al., 2009; Szatrowski and Nathan, 1991 (Caltagirone et al., 2001; Ibrahim et al., 2013; Pantopoulos et al., 1997) , and a growing body of literature suggests that, in general, cancer cells demonstrate increased levels of intracellular labile iron (Torti and Torti, 2013) . Given these previous observations, we hypothesized that increased mitochondrial-derived ROS leading to disruptions in cellular iron metabolism may underlie the selective mechanism of ascorbate toxicity.
Supporting this hypothesis, following lobectomy, fresh frozen NSCLC tissue, demonstrated increased steady-state levels of O 2 •− as determined by superoxide dismutase (SOD) mimetic (GC4419)-inhibitable dihydroethidium (DHE) oxidation ( Figure 5A ; Figures S4, S5A), as well as increased labile iron ( Figure 5B ; Figure S4 ) compared to adjacent normal tissue. These results support the hypothesis that increased steady-state levels of O 2 •− lead to an increased LIP that could sensitize cancer cells to ascorbate in human tissues.
To directly test this hypothesis, the CRISPR/Cas9 system was utilized to delete the mitochondrial superoxide dismutase gene, SOD2, in A549 NSCLC cells (SOD2 −/− ) (Figures S5B, S5C), which are relatively resistant to ascorbate-mediated cell killing. As predicted, SOD2 −/− cells demonstrated increased steady-state levels of O 2
•− ( Figure 5C ), a significantly increased LIP ( Figure 5D ), as well as increased susceptibility to pharmacological ascorbateinduced clonogenic cell killing ( Figure 5E Consistent with results from a large immunohistochemical study demonstrating increased transferrin receptor (TfR) levels in NSCLC tissue as compared to adjacent normal lung tissue (Kukulj et al., 2010) , NSCLC and GBM cell lines demonstrated increased TfR levels compared to HBEpCs or NHAs, respectively ( Figure 5F ; Figure S5J ) Interestingly, in cancer cells, increased TfR is seen in the context of increased labile iron content ( Figure 5B Figure 5J ). Consistent with the proposed mechanism that the lower LIP in normal cells limits ascorbate toxicity, exposure of NHAs to exogenous Fe 2+ , as FAS, increased the intracellular LIP and sensitized NHAs to ascorbate toxicity ( Figure 5K ). Together, these data support the conclusion that cancer-cell specific increases in LIP, as a result of perturbed mitochondrial O 2 •− metabolism, significantly contributes to the differential sensitivity of human lung and brain cancer cells to ascorbate toxicity.
Ascorbate selectively increases cancer cell LIP through H 2 O 2 -mediated disruptions of Fe-S containing proteins
In addition to basal differences in labile iron (
Figure 5B (Boyer and McCleary, 1987; Moser et al., 2014) . Importantly, although these doses induce cancer cell clonogenic cell killing, metabolic viability determined with trypan blue dye or the reduction of resazurin 1-1.5 hr post ascorbate exposure was unchanged, demonstrating that changes in LIP seen at 1 hr are not a consequence of metabolic cell death ( Figure S6B ). In intact cells, disruption of the integrity of Fe-S cluster proteins may contribute to ascorbate-mediated increases in LIP as evidenced by the inactivation of the Fe-S cluster-containing proteins aconitase and mitochondrial ETC complexes I and II, while having no effect on ETC complex IV activity, which contains no Fe-S clusters ( Figure 6C, 6D Figure S6E ).
Pharmacological ascorbate is safe, tolerable, and potentially efficacious in combination with radio-chemotherapy in GBM and advanced stage NSCLC These preclinical studies in GBM led to a phase I clinical trial assessing the safety and tolerability of pharmacological ascorbate in combination with ionizing radiation (IR) and temozolomide (TMZ) in GBM subjects (NCT 01752491) (Table S2 ; Figure S7A ). Following maximum safe surgical resection or biopsy (if unresectable), subjects received radiation (daily), temozolomide (daily), and intravenous (IV) ascorbate infusions (three times a week) for approximately 7 weeks (radiation phase; Stupp et al., 2005a) . For each subsequent subject, ascorbate doses were escalated during the radiation phase (15 -125 g infusion) with a 20 mM target plasma concentration (infusion dose denoted next to each subject # in Figure  7A ; Welsh et al., 2013) . Following conclusion of the radiation phase, all subjects were dose escalated to achieve ≥ 20 mM plasma ascorbate in combination with temozolomide for approximately 28 weeks (for a total therapy duration of ~35 weeks; Figure 7A ). The desired mean therapeutic blood level was achieved in all subjects receiving the 87.5 g infusions ( Fig.  7B ; Figures S7B, S7C ).
Pharmacological ascorbate was safe and well tolerated in all 13 subjects who participated in the trial with minimal grade 3 and 4 toxicities, which compared favorably to Stupp et al. (2005) (Tables S3, S4 ). Non-hematological toxicities observed in the phase 1 trial during the radiation phase included grade 2 and 3 fatigue, grade 2 and 3 nausea, grade 2 infection, and grade 3 vomiting. In the adjuvant phase, observed toxicities included grade 2 fatigue, grade 2 nausea, grade 1 vomiting, grade 3 leukopenia, and grade 3 neutropenia. No serious adverse events in the radiation phase or adjuvant phase were ascribed to pharmacological ascorbate treatment and all subjects maintained their performance status throughout the treatment.
Although the small number of subjects prevent a statistically significant assessment of efficacy (11 subjects; 2 subjects were removed from longevity analysis due to limited protocol dictated therapy due to unrelated co-morbidities), average progression free survival (PFS) currently stands at 13.3 months (median: 9.4 months) vs. the historical median PFS of 7 months (Stupp et al., 2005a) , and average overall survival (OS) is currently 21.5 months (median: 18.2 months) vs. historical median of 14 months. Furthermore, 4 subjects remain alive, with 1 showing no evidence of disease based on MR imaging ( Figures 7A, 7C) . Importantly, the characteristics of the subject population were not significantly different than the subject characteristics from Stupp et al. (2005) (Table S5 ).
Most interestingly, a companion study published by Stupp et al. (2005) analyzed the methylation status of the O 6 -methylguanine-DNA methyltransferase gene (MGMT) promoter (Hegi et al., 2005) and demonstrated a significant reduction in survival in GBM subjects receiving concurrent radiation and temozolomide that lacked MGMT promoter methylation (median overall survival = 12.7 vs. 21.7 months). In the Stupp et al. (2005) trial (Hegi et al., 2005) , MGMT promoter methylation was absent in 57% of the GBM subjects.
In comparison, MGMT promoter methylation was absent in 73% of the subjects in the current phase I clinical trial and median overall survival for subjects lacking MGMT promoter methylation is 23.0 months (vs. 12.7 months in Hegi et al., 2005) . Additionally, 3 of 8 subjects lacking MGMT promoter methylation in the current trial remain alive, with 1
showing no evidence of disease based on MR imaging ( Figures 7A, 7D ).
Furthermore, the initial results (n = 14 subjects) from a phase II clinical trial assessing the efficacy of pharmacological ascorbate with platinum-doublet chemotherapy in advanced stage NSCLC (NCT 02420314) ( Figure S8A ; Table S6 ) also demonstrate promising results in achieving therapeutic ascorbate blood levels (16.4 ± 0.5 mM; Figure S8B , S8C) and achieved a disease control rate of 93% and a confirmed objective response rate of 29%, as compared to historical controls with 40% disease control rates and 15-19% confirmed objective response rates ( Figure 7E , 7F) (Schiller et al., 2002; Sandler et al., 2006) .
Discussion
The combination of high-dose intravenous and oral ascorbate was first proposed as a potential anti-cancer agent in 1976 (Cameron and Pauling, 1976) . However, two randomized clinical trials testing the efficacy of high-dose oral ascorbate failed to demonstrate any effect on survival (Creagan et al., 1979; Moertel et al., 1985) . Subsequent pharmacokinetic studies demonstrated the inability of oral ascorbate dosing to reach therapeutic plasma levels (Padayatty et al., 2004) . This finding revitalized interest in ascorbate as an adjuvant to cancer therapy and demonstrated the need to confirm plasma levels of ascorbate to ensure therapeutic concentrations are achieved (Welsh et al., 2013) . With this more complete understanding of ascorbate pharmacokinetics, this work, and others in pancreatic and ovarian cancer, have consistently demonstrated selective toxicity to cancer cells as compared to normal cells both in vitro and in vivo (Du et al., 2010; Monti et al., 2012; Welsh et al., 2013; Ma et al., 2014) . Furthermore, the results of the current clinical trials, together with the results of all previous clinical trials that we are aware of, continue to demonstrate a lack of ascorbate toxicity in normal tissue when combined with chemotherapy or radiochemotherapies. Additionally, preliminary data from both the GBM and NSCLC trials presented here show promising results for potentially increasing efficacy of current treatment regimens.
The mechanism underlying the cancer cell-selective toxicity of ascorbate has remained incompletely understood since Cameron and Rotman first hypothesized the utility of pharmacological ascorbate in cancer therapy (Cameron and Rotman, 1972) . Recently, Yun et al. hypothesized that the selective toxicity of ascorbate in KRAS and BRAF mutant clones was facilitated by increased glucose transporter (GLUT)-mediated uptake of dehydroascorbate and subsequent NAD + depletion and energetic crisis (Yun et al., 2015) . In the current study, GLUT-mediated DHA uptake demonstrated a minimal role in ascorbate toxicity in these model systems. Furthermore, consistent with the mechanism of ROSmediated disruptions in cellular iron metabolism underlying the selective toxicity of ascorbate, KRAS and BRAF mutant cells have been suggested to demonstrate increased (Doskey et al., 2016) in the presence of a restricted labile iron pool, and the antioxidant actions of ascorbate prevail. In support of this, pharmacological ascorbate has been proposed to protect IR-mediated damage to jejunal crypts in mice (Du et al., 2015b) and decrease chemotherapy-associated adverse events in ovarian cancer subjects (Ma et al., 2014) .
Since cancer cells, in general, have been hypothesized to demonstrate increased steady-state levels of O 2 •− and H 2 O 2 due to fundamental defects in oxidative metabolism (Bize et al., 1980; Spitz et al., 2000; Aykin-Burns et al., 2009; Oberley et al., 1980) and increased labile iron (Torti and Torti, 2013; Caltagirone et al., 2001; Ibrahim et al., 2013; Pantopoulos et al., 1997) , the current findings, combined with similar findings in pancreas and ovarian cancer (Monti et al., 2012; Welsh et al., 2013; Ma et al., 2014) , continue to support the potential for the general application of pharmacological ascorbate in cancer therapy. Given these data, ascorbate may represent an easily implementable addition to current anti-cancer therapies and further large-scale clinical studies are warranted to determine the overall efficacy of ascorbate in NSCLC and GBM. Finally, manipulations of redox active metal ions in cancer cells may represent both a target and a biomarker for predicting responses to pharmacological ascorbate in cancer therapy.
STAR Methods
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Douglas R. Spitz (douglas-spitz@uiowa.edu).
Experimental Model and Subject Details
Cell Lines and Primary Cultures-NSCLC cell lines H292 (source: female), H1299 (source: male), H23 (source: male), and A549 (source: male) and HEL 92.1.7 cells (source: male) were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). Normal human bronchial epithelial cells (HBEpC) were gown in proprietary HBE medium and growth supplements (Cell Applications, Inc). HBEpCs from both a male and female source were utilized in this manuscript. GBM cell lines U87 (source: male), U118 (source: male), U251 (source: male), and normal human astrocytes (NHA) (sources: two male cultures) were grown in DMEM F12 medium supplemented with 15% FBS, 10 μg mL −1 insulin, 7.5 ng mL −1 fibroblast growth factor (FGF), 1 mM sodium pyruvate, 15 mM HEPES buffer (pH 7.2), and 100 units/100 μg mL −1 penicillin/streptomycin.
As primary cells in culture grow better under normoxic conditions (4% O 2 ) (Packer and Fuehr, 1977) and this manuscript investigates intrinsic differences between cancer and primary cells, all cells were incubated at 4% O 2 in a humidity controlled environment (37 °C, 5% CO 2 ; Forma Scientific). Importantly, we did not see any difference in toxicity in cancer cells exposed to ascorbate for 1 hr in 21% or 4% O 2 (data not shown). In all experiments utilizing HEL 92.1.7 and A549 parental and SOD2 −/− cells, cells were maintained and experiments were performed at 21% O 2 to maximize effects on superoxide production. All cell lines were utilized before passage 20 and treated in exponential growth phase at 50-75% confluence. Doubling times of HBEpCs and NHAs were monitored and cells were utilized until doubling time increased by 50%.
In Vivo Mouse Studies-Female 4-6 week old athymic nude mice (Foxn1 nu /Foxn1 nu )
were purchased from Envigo (previously Harlan Laboratories) and housed in the Animal Care Facility at The University of Iowa (Iowa City, IA), and all procedures were approved by The University of Iowa Institutional Animal Care and Use Committee and conformed to NIH guidelines. All mice were treatment naïve at the time of tumor cell introduction. For all xenograft studies, after tumors were established, mice were randomly assigned to experimental groups. Mouse weights throughout the experiments are illustrated in Figure  2C .
Clinical Trials-For the phase I clinical trial evaluating the safety of combining pharmacological ascorbate with standard radiation and temozolomide in glioblastoma (GBM) patients, approval was sought, and obtained, from The University of Iowa Institutional Review Board (Biomedical IRB-01; IRB 201211713). For the phase II clinical evaluating the efficacy of combining carboplatin and paclitaxel with pharmacological ascorbate in advanced stage (stage IIIB and IV) NSCLC patients, approval was sought, and obtained, from The University of Iowa Institutional Review Board (Biomedical IRB-01; IRB 201412760). Both trials were registered with clinicaltrials.gov prior to enrollment of the first subject (NCT01752491 and NCT02420314, respectively). Both clinical trials were conducted compliant with good clinical practice, including obtaining informed consent directly from all trial participants; none of the elements of consent were waived.
Method Details
Ascorbate and Ascorbate Exposure-L-Ascorbic acid stock solution (approx. 1 M) was made in Nanopure ® Type 1 water (18 MΩ) with the pH adjusted to 7.0 with 1 M NaOH, stored in sealed glass tubes with minimal head space, and the precise concentration was confirmed spectrophotometrically as previously described (265 nm, ε = 14.5 mM −1 cm −1 ) (Buettner, 1988) . For all experiments directly comparing the effects of ascorbate on cancer and normal cells, ascorbate is dosed per cell due to previous literature demonstrating that H 2 O 2 and ascorbate toxicity is dependent on cell number/density (Doskey et al., 2015; Spitz et al., 1987) . Furthermore, the media conditions, including media volume, during cancer vs. normal comparisons are identical, as media constitution (i.e. serum, pyruvate and other α-ketoacids, metal ions, etc.) and media pH (i.e. lactate production) modulate ascorbate toxicity and can account for apparent differences in cell sensitivity to ascorbate within a given cell type (Buettner, 1988; Spitz et al., 1987; Olney et al., 2013; Nath et al., 1995; Clément et al., 2001; Mojić et al., 2014) . For NSCLC and HBEpC comparisons, cells were exposed to ascorbate in serum-free RPMI supplemented with HBE media supplements and returned to their normal maintenance media for cloning. For clinical dosing, the studies utilize commercially available, prescription-only L-ascorbic acid for intravenous injection (500 mg mL −1 ).
Although the data investigating tissue ascorbate concentrations following pharmacological ascorbate administration is limited, initial measurements of ascorbate levels in syngeneic mice bearing Lewis lung carcinoma tumors following 1 g kg −1 IP ascorbate resulted in peak plasma concentrations of 4.7 ± 0.6 mM that resulted in peak tumor tissue homogenate concentrations of 1.04 μmoles g −1 wet weight (Campbell et al., 2016) . This would convert to approximately 1.04 mM tissue concentrations assuming the wet weight of tissue is approximately the same as H 2 O (1 g mL −1 ). In a different study when nude mice with 9L glioma xenografts were treated with 4 g kg −1 ascorbate IP (Chen et al., 2008) , peak tumor concentrations of >30 mM ascorbate were reported. Given these previous results, all in vitro ascorbate doses utilized in the current report (0.5-20 mM) are well within the range of likely ascorbate concentrations achieved in tumor and normal tissues in vivo (Campbell et al., 2016; Chen et al., 2008) .
Ionizing Radiation-Ionizing radiation (IR) was delivered in the Iowa Radiation and Free Radical Research Core facility using a Pantak Therapx DXT 300 X-ray machine operated at 200 kVp with added filtration of 0.35 mm Cu + 1.5 mm Al, resulting in a beam quality of 0.95 mm Cu. For in vitro studies, cells were irradiated in 60 mm cell culture dishes. For in vivo murine xenograft studies, mice were anesthetized using an 87.5 mg kg −1 ketamine and 12.5 mg kg −1 xylazine mixture and placed in lead boxes with only their right flank exposed.
Clonogenic Survival, Viability, and Metabolic Activity Assays-Cells (1-2 × 10 5 ) were plated in 60 mm cell culture dishes and grown in their respective media for 48 hr before exposed to experimental conditions. For radio-chemotherapy sensitization experiments, the cells were sequentially exposed to 1 h chemotherapy, 1 h pharmacological ascorbate, and then 2 Gy IR. For bovine catalase experiments, catalase was added 1 min prior to ascorbate exposure. For AdGPx1 experiments, cells were supplemented with 30 nM sodium selenite following transduction and throughout clonogenic growth. For iron chelation or iron addition experiments, chelators were added 3 hr prior to and during ascorbate exposure to ensure that labile metal ions were sufficiently bound. For experiments investigating the role of intracellular versus extracellular iron, chelators were either added 3 h prior to ascorbate exposure and washed before ascorbate exposure, or media that was to be added later during ascorbate exposure was pre-chelated for 3 hr at 37 °C. For experiments testing the ability of AntA to sensitize NHAs to ascorbate, trypsinized NHAs were exposed in solution to 25 μM AntA in the presence or absence of 10 pmol cell −1 (2 mM) AscH − prior to flow cytometry or clonogenic cell survival analysis. Resazurin (a.k.a. Alamar Blue) was utilized to assess metabolic activity. Following 1 hr exposure to ascorbate, cells were washed, and stained in 6 μM resazurin for 1.5 h at 37 °C. Cells were then washed twice in PBS, trypsinize d, and spun at 1200 rpm × 5 min. Pellets were resuspended in PBS and 10,000 cells were assayed for the reduction of resazurin (nonfluorescent) to resorufin (fluorescent) and analyzed on a LSR II Flow Cytometer (BD Biosciences; λ ex = 561 nm, λ em = 582/15 nm).
Murine Xenograft Models-1 × 10 6 H292 or U87 cells were injected subcutaneously into the right rear flank. Once tumors were established, treatment was initiated with daily ascorbate (4 g kg −1 or equivalent dose of NaCl, IP), weekly carboplatin (5 mg kg −1 for H292) or temozolomide (2.5 mg kg −1 for U87), and/or IR (12 Gy/2 frx). Ascorbate/NaCl and chemotherapy was continued for the full extent of the study. Tumors were measured every other day with Vernier calipers (volume = (length × width × (width/2)) and mice were euthanized and sacrificed when tumor length exceeded 1.5 cm in any dimension.
Ascorbate Quantification-Tumor xenografts were excised and flash frozen in liquid nitrogen until analysis. Cell culture lysates were collected, and immediately assayed for ascorbate concentration. Mouse whole blood was collected by cardiac puncture, and plasma was collected after the sample was centrifuged at 500 g for 10 min and frozen until analysis. For patient samples, whole blood was collected from clinical trial patients (NaHeparin 75 USP units, BD Vacutainer ® green top blood collection tube, 4 mL), and plasma was collected after centrifugation at 500 g for 10 min and aliquoted and stored at −80 °C until analysis.
Total ascorbate in cell culture lysates, mouse samples, and GBM subjects was quantified as previously described (Vislisel et al., 2007; Welsh et al., 2013) . Briefly, samples were extracted in a buffer containing 90% methanol and 10% water with 250 μM DETAPAC (90:10, v/v), mixed, and incubated on ice for 10 min to precipitate protein. The samples were clarified by centrifugation (16 g, 10 min) with an Eppendorf model 5415D Microfuge. Specifically, samples were diluted at a ratio of 50 μL of plasma to 450 μL extraction buffer. These samples were then further diluted another 77.5 to 105-fold (therefore, 775 to 1,050 fold overall) in a buffer containing 72% methanol and 28% water with 250 μM DETAPAC (72:28, v/v). L-ascorbic acid standards were prepared in 72% methanol and 28% water with 250 μM DETAPAC (72:28, v/v) with stock solution concentrations ranging from 2.5 to 50 μM. This protocol ensured that all samples had identical methanol content which is critical for accurate quantification (Vislisel et al., 2007) .
Aliquots (100 μL) of the samples or standards were placed in 96-well optical bottom black plates (Thermo Fisher Scientific, Rochester, NY, USA). The assay was initiated at room temperature by adding 100 μL of 2.3 mM 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxyl (Tempol) in 2 M sodium acetate trihydrate buffer previously adjusted to pH 5.5 with acetic acid. The samples were then incubated for 10 min in the dark, allowing for Tempol-mediated oxidation of ascorbate to dehydroascorbate (DHA). Subsequently, 42 μL of 5.5 mM orthophenylenediamine (oPDA) in 2 M sodium acetate buffer (pH 5.5) was added to the samples. Kinetic measurements were immediately initiated and collected every 22 s using a TECAN SpectraFluor Plus plate reader (Tecan, Research Triangle Park, NC, USA) for the fluorescent condensation product of the reaction of oPDA with DHA (3-(dihydroxyethyl)furo[3,4-b]quinoxaline-1-one; λ ex = 345 nm, λ em = 425 nm). Plasma ascorbate concentrations were determined against the linear portions of the standard curve and corrected for previous dilutions.
Total ascorbate in NSCLC subject's plasma was quantified as previously described (Witmer et al., 2016) . Briefly, plasma samples were measured spectrophotometrically (265 nm; ε = 13,000 M −1 cm −1 ) using an Implen Nanophotometer P-330 with a 250x dilution lid, path length = 4.00 × 10 −3 cm. The blank for each sample was a pair-'pre-infusion' plasma sample, which allowed removal of the background absorbance of plasma proteins and other constituents.
CSF Ascorbatel Radical Electron Paramagnetic Resonance (EPR)-CSF was
collected from nude athymic female mice that had received daily IP injections of ascorbate (4 g kg −1 ) for two weeks as previously described (Liu and Duff, 2008) . Briefly, mice were anesthetized (17.5 mg ml −1 ketamine/2.5 mg ml −1 xylazine mixture), restrained in a stereotaxic frame with an acute head angle, and the dura mater covering the foramen magnum was surgically exposed. CSF was collected by capillary action following minimal puncture of the dura mater and frozen until EPR analysis. Ascorbate radical EPR spectra were obtained by placing the capillary tube into the bottom of a 250 mm × 3 mm (ID) thin walled quartz EPR tube (707-SQ-250M Wilmad-Lab Glass, Vineland, NJ) centered in a Bruker HS EPR cavity (Bruker, Billerica, MA). Spectra of the ascorbate radical (g = 2.0052) were acquired by a Bruker EMX EPR spectrometer at room temperature while using a microwave power of 3.2 mW; frequency, 9.858 GHz; scanning 10 G with a sweep time of 20.972 s; receiver gain, 5.02 × 10 4 ; modulation frequency, 100 kHz; modulation amplitude, 0.70 G; signal channel time constant, 327.680 ms. Spectra were collected in the additive mode using 5 scans.
Adenovirus Transduction-Replication-incompetent adenoviral vectors, Ad-empty (AdE), 25 MOI AdCMV catalase (AdCat), 25 MOI AdCMV glutathione peroxidase 1 (AdGPx1), 50 MOI AdCMV SOD1 (AdSOD1), and 50 MOI AdCMV SOD2 (AdSOD2) vectors are previously described (Zwacka et al., 1998; Ahmad et al., 2005 Ahmad et al., , 2008 . 20 MOI AdFerritin heavy and light chain (AdFtH and AdFtL, respectively) were generated by ViraQuest (North Liberty, IA) using commercially available iron regulatory element (IRE)-lacking vectors (OriGene). All transductions were performed in serum-free DMEM for 8-12 hr once cells reached 50-70% confluency. Cells were washed and grown in full media for an additional 36 hours before experiments were conducted. All transductions were confirmed by activity assay and/or western blot for each individual experiment.
Radiolabeled 14 C-EDTA Uptake-H292 NSCLC cells were exposed to 1 mM 'cold' EDTA spiked with 5 × 10 5 predicted disintegrations per minute (DPM) 14 C-EDTA, which had a negligible effect on overall EDTA concentration, for 3 hr. To control for any effects of salt composition on radioactivity quantification, all sample vials contained 15 mL liquid scintillation cocktail + 5 mL of media, PBS, or trypsin. All samples were divided into 'media,' 'wash,', or 'cells' vials. The 'media' vial contained 4 mL spiked media + 1 mL PBS wash. The 'wash' vial contained 5 × 1 mL wash. The 'cells' vials contained 1 mL tyrpsin + H292 cells + 4 × 1 mL PBS washes. For the standard curve, all standards were added to 5 mL PBS + 15 mL liquid scintillation cocktail. All radioactive counts were collected on a liquid scintillation counter (Beckman #L2100) and fraction of EDTA in samples were calculated after subtraction of background counts:
Human Tissue Sample Collection and Inclusion Metrics-Tumor and adjacent normal was collected from patients with suspected or confirmed NSCLC patients through the IRB-approved University of Iowa Tissue Procurement Core and was frozen in TissueTek ® O.C.T. Compound. A board certified pathologist from the University of Iowa Hospital and Clinics histologically confirmed the NSCLC diagnosis. Samples were utilized for further studies if histology revealed >75% tumor or normal tissue, respectively, in adjacent tissue slices both before and after the samples were collected.
Tissue DHE Staining and Quantification-From OCT-frozen patient tissue, 10 μm sections of both tumor and adjacent normal tissue were cut and placed on the same slide to control. Tissue sections were stained with 10 μM DHE for 30 min in PBS + 5 mM sodium pyruvate prior to analysis by confocal microscopy (Olympus FLUOVIEW FV1000). For treatment groups, tissue sections were pretreated for 30 min with 0.25 μM GC4419 SOD mimetic or, alternatively, as a positive control, tissue sections were co-treated with 10 μM antimycin A (AntA) during the last 15 min of DHE staining. Each image obtained was quantified by measuring the mean fluorescence intensity of at least 200 cell nuclei (ImageJ), and normalized to nuclei from untreated normal tissue cell nuclei.
To test the specificity of GC4419, any reaction with H 2 O 2 was tested spectrophotometrically (240 nm; ε = 39.4 M −1 cm −1 ) by measuring the disappearance of H 2 O 2 in the presence of 0.25 μM GC4419 or 15 mkU mL −1 bovine catalase in 50 mM phosphate buffer (pH 7.0).
Tissue Iron Quantification-Labile iron in patient NSCLC and adjacent normal tissue was quantified as previously described (Moser et al., 2014) . Wherever possible, metal instrumentation was avoided to prevent contamination from adventitious labile iron. Briefly, tissue sections were homogenized in a 1.5 mL eppendorf tube by plastic pestle in 350 μL PBS (pH 6.5) that was previously treated with Chelex® 100 beads to remove any adventitious labile iron. To this homogenate, 2 mM DFO (final concentration) was added and samples were incubated on ice for 1 hr and frozen at −80 °C unti l analysis. For analysis, samples were placed in 4 mm O.D. EPR tubes (Wilmad-LabGlass, Vineland, NJ, 707-SQ-250M) and were flash frozen in liquid nitrogen. The samples were then analyzed for labile iron by using EPR (Bruker EMX EPR spectrometer), monitoring for the high spin ferrioxamine (Fe 3+ -DFO) signal at g = 4.3 at 100 K (Bruker ER4111VT variable temperature accessory) with the following EPR instrument parameters: center field 1575 G, sweep width 500 G, typical microwave frequency 9.766 GHz, power 20 mW, receiver gain 2 × 10 5 , modulation frequency 100 kHz, modulation amplitude 2 G, time constant 163.84 ms, conversion time 20.48 ms, resolution 1024 points, and with 5 additive scans. All samples were analyzed three times, repositioning the sample in the cavity before initiating each additional scan. The mean signal intensity was quantified and the labile iron content was calculated using a standard curve (0 -15 μM FAS with 1 mM DFO) and normalized to total tissue protein by the Pierce ™ BCA protein assay kit (ThermoFisher Scientific), which is not susceptible to interference from residual OCT as opposed to the Lowry method (data not shown). Furthermore, equimolar DFO was added into the standard curve to control for any potential interference of DFO in the assay system (data not shown).
CRISPR/Cas9-Mediated Deletion of SOD2-The CRISPR/Cas9 system was utilized to delete mitochondrial SOD2 from A549 and HEL 92.1.7 cells as previously described in HEK293T cells (Cramer-Morales et al., 2015) . Briefly, cells were electroporated (200 V, 30 μF) with the custom synthesized pD130-GFP expression vector containing expression cassettes for green fluorescent protein (GFP), Cas9 endonuclease, and a CRISPR chimeric cDNA with a gRNA moiety designed to target SOD2 (DNA 2.0, Menlo Park, CA). Cells that transiently expressed GFP were sorted by flow cytometry and cloned. Deletion of SOD2 was confirmed by western blot and activity assays ( Figure S5 ).
SOD Activity Assay-MnSOD activity was measured in cell lysates as previously described (Spitz and Oberley, 2001) . Briefly, dry cell pellets were homogenized in 50 mM phosphate buffer with 1.34 mM DETAPAC. To measure MnSOD activity only, the sample is incubated with 5 mM NaCN − for 30 min to inhibit CuZnSOD activity. To measure the MnSOD activity, the rate of nitroblue tetrazolium (NBT) reduction was measured during the reaction of 100 μL of increasing amounts of total sample protein (0 -500 mg), 100 μL of 10 −2 U mL −1 xanthine oxidase, and 800 μL of 50 mM phosphate buffer (1 mM DETAPAC, 0.13 mg mL −1 BSA, 1.0 U mL −1 catalase, 5.6 × 10 −5 M NBT, 1 × 10 −4 M xanthine, 5 mM NaCN − , 50 μM bathocuproine disulfonic acid) at 560 nm for 2 min. One unit of SOD activity is measured as the amount of protein necessary to reach 50% of maximum inhibition of NBT reduction.
To account for incomplete CN − -mediated inhibition of CuZnSOD activity, MnSOD and CuZnSOD activity was more specifically differentiated by a SOD activity gel as adapted from techniques previously described (Ornstein, 1964) . Briefly, a 12% polyacrylamide gel was made and pre-electrophoresed for 1 hr at 40 A (188 mM Tris-base, 1.3 mM EDTA, pH 8.8). The following day, a 5% polyacrylamide stacking gel with 0.004% riboflavin-5′-phosphate with a 1.5 mm comb was solidified under a fluorescent light for 15 -30 min. 100 μg total protein was electrophoresed for approximately 3 hr at 40 A (50 mM Tris base, 300 mM glycine, 2.3 mM EDTA, pH 8.3) while the gel electrophoresis box was placed in a ice bath to maintain protein activity. The gels were then soaked in the staining solution (2.43 mM NBT, 28 mM TEMED, 2.8 × 10 −5 M riboflavin-5′-phosphate in ddH 2 O) for 20 min at room temperature in the dark. The gels were then rinsed, placed in 50 mM phosphate buffer (pH 7.8) and exposed to fluorescent light to initiate superoxide production. Achromatic bands indicate the presence of SOD activity. Once developed, the gels were further developed at room temperature overnight and imaged.
Cellular Labile Iron Pool Quantification-The labile iron pool (LIP) was visualized using the fluorescent dye Calcein-AM as previously described with modifications (Epsztejn et al., 1997) . Briefly, after sample treatment, cells were trypsinized, spun at 1,200 rpm for 5 min, and resuspended at approximately 1 × 10 6 cells mL −1 in 500 nM Calcein-AM in PBS. Samples were incubated for 15 min at 4% O 2 in a humidity controlled environment (37 °C, 5% CO 2 ). Subsequently, samples were pelleted, washed in PBS, and resuspended in 1 mL PBS before dividing each sample into two flow cytometry sample tubes, to which 100 μM 2′,2′-bipyridyl (BIP) was added to one tube. Samples were kept at room temperature and 10,000 cells were analyzed on a LSR II Flow Cytometer (BD Biosciences; λ ex = 488 nm, λ em = 515/20 nm). BIP tubes were incubated for at least 15 minutes before analysis to allow for full chelation of intracellular labile iron. The LIP (A.U.) = MFI BIP -MFI NoBIP was normalized against the control samples to calculate the relative labile iron pool.
To determine any interaction with ascorbate, BIP-mediated change in calcein fluorescence (100 nM Calcein; 20 nM FAS) was measured in Luminescence Spectrometer LS 50B (Perkin Elmer) in the presence or absence of 5 mM ascorbate after incubation at 37 °C for 20, 40, or 60 min.
Western Blots-Exponentially growing cells were washed with PBS before the addition of lysis buffer (Cell Signaling), incubated on ice for 5 minutes, and scraped. The lysate was collected and centrifuged to remove cellular debris. The protein concentrations were determined on the cleared lysate using the Bio-Rad DC Bradford Protein Assay (Bio-Rad Laboratories, Hercules, CA. Total protein (25μg) was electrophoresed on a 4-20% gradient gel (Bio-Rad) at 80 V for approximately 1 h. The separated proteins were transferred onto PVDF membrane (Millipore, Billerica, CA) and non-specific binding was blocked using 5% nonfat dry milk in PBS-Tween (0.2%) for 1 hr at room temperature. The membranes were incubated with primary antibodies (Ferritin heavy chain, 1:1000, Ferritin light chain 1:10,000, both antibodies from Abcam, Cambridge, MA, Transferrin receptor, 1:1000, Invitrogen, Camarillo, CA) at 4° C overnight. Actin served as a loading control (1:4,000; Sigma-Aldrich). Following 3 × 5 min PBS-Tween washes, the membranes were blotted with secondary antibodies (1:25,000; Sigma-Aldrich, St. Louis, MO) that were conjugated with horseradish peroxidase for 1 hour. The washed membranes were incubated with Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) and exposed to CareStream BioMax MR Film (CareStream Health, Rochester, NY). Quantification of western blots were performed in ImageJ.
Transferrin Receptor siRNA-For siRNA-mediated knockdown of TfR, we utilized a commercially available pre-validated siRNA construct (s727, Silencer ® Select; Ambion, Life Technologies, ThermoFisher Scientific) as well as a scrambled siRNA transfection control (Silencer® Select Negative Control No. 1). Cells were plated and allowed to grow 36-48 hr until they reached 30-40% confluence. siRNA (25 pmol per dish) and Lipofectamine ® 2000 (10 μL per dish) were prepared as instructed in OptiMEM transfection media (Gibco). A master mix of siRNA (25 pmol per dish) and lipofectamine (10 μL per dish) were individual diluted in 500 μL OptiMEM per dish and allowed to incubate for 5 min at room temperature. These solutions were then combined, mixed gently, and allowed to incubate for an additional 20 min before adding 1 mL of the solution to each washed cell culture dish. The cells were exposed to the transfection medium for 8 -12 hr, washed, and grown in full media until 80 -90% confluence (~36 h). Further experiments were conducted as described above. Because TfR mRNA is mostly regulated post-transcriptionally, and our endpoint was knockdown of TfR, knockdown in each experiment was confirmed by western blot of immune-reactive TfR protein (representative image: Fig. 4M )
Aconitase Activity-Exponentially growing cells were scraped and frozen as dry pellets until assayed for total aconitase activity adapted from as previously described (Case et al., 2011) . Briefly, cell pellets were resuspended in 50 mM Tris-HCl, pH 7.4 with 0.6 mM MnCl 2 and 5 mM Na-citrate and sonicated 3 × 10 s each. Protein was quantified by the Lowry method (Lowry et al., 1951) . Aconitase activity was measured as the rate of appearance of NADPH (at 340 nm; Beckman DU 800 spectrophotometer, Brea, CA) for 45 min during the reaction of 200 μg total sample protein with 200 μM NADP + and 10 U isocitrate dehydrogenase.
ETC Complex Activity-Exponentially growing cells were scraped and frozen as dry pellets until assayed for protein content (Lowry) and maximal ETC complex activity as previously described (Birch-Machin et al., 1994) . Briefly, dry cell pellets were resuspended in 20 mM potassium phosphate buffer and sonicated 3 × 10 s each. Rates of activities were normalized to total protein. Complex I activity was quantified as the rate of rotenoneinhibitable NADH oxidation (320 nm; ε = 6.22 mM −1 cm −1 ). Samples were assayed in the presence or absence of 200 μg mL −1 rotenone in 25 mM potassium phosphate working buffer (5 mM MgCl 2 , 2 mM KCN, 2.5 mg mL −1 BSA, 0.13 mM NADH, 200 μg mL −1 antimycin A, 7.5 mM coenzyme Q 1 ). Complex II activity was measured in the presence and absence of 0.2 M succinate in 25 mM potassium phosphate working buffer (5 mM MgCl 2 , 2 mM KCN, 2.5 mg mL −1 BSA for 10 minutes at 30 C. After incubation, 200 μg mL −1 antimycin A, 200 μg mL −1 rotenone, 5 mM 2,6-dichloroindophenol (DCIP), and 7.5 mM coenzyme Q 1 were added to each cuvette and incubated for 1 min before quantifying Complex II activity as the difference in the rate of DCIP reduction in the presence and absence of succinate (at 600 nm; ε = 19.1 mM −1 cm −1 ). Complex IV activity was assayed as the rate of oxidation of cytochrome c (500 nm; ε = 19.6 mM −1 cm −1 ). Whole cell lysates were assayed in 25 mM potassium phosphate buffer (0.5 mM n-dodecyl β-maltoside, 1.5 mM reduced cytochrome c).
Quantification of Intracellular H 2 O 2 with PeroxyOrange-1-To visualize intracellular H 2 O 2 levels, the selectively sensitive fluorescent probe PeroxyOrange-1 was utilized as previously described with modifications (Dickinson et al., 2010) . 1 × 10 5 cells were plated and grown in their respective media for 48 hr. The complete protocol was conducted in the dark with minimal ambient lighting. Cells were washed with PBS and incubated with 10 uM PO-1 in phenol red free RPMI supplemented with HBE growth supplements for 1 hr at 37 °C. Cells were then washed in PBS and placed back in phenol red free RPMI supplemented with HBE growth supplements. At this time, treatment with 15 pmol cell −1 ascorbate or 100 μM H 2 O 2 (every 30 min) was initiated and cells were placed back at 37 °C. At times indicated, cells were placed on ice for the remainder of the protocol, washed, and trypsinized with phenol red free 0.5% trypsin. After 15 min, cells still attached were scraped and all cells were collected in 15 mL conical vials containing PBS + 10% FBS to neutralize the trypsin reaction. Cells were spun at 1200 rpm for 5 min at 4 °C, resuspended in 300-500 uL PBS and 10,000 cells were analyzed on a LSR II Flow Cytometer (BD Biosciences) with λ ex =561nm, λ em =585/20nm. The mean fluorescence intensity (MFI) was analyzed (FlowJo ™ ) and corrected for autofluorescence against unlabeled cells. Normalized MFI was calculated by comparing MFI for a given treatment group against control.
To determine any interaction with ascorbate PO-1 fluorescence (10 μM PO-1, 100 μM H 2 O 2 ) was measured in Luminescence Spectrometer LS 50B (Perkin Elmer) in the presence or absence of 1 mM ascorbate.
Phase I Clinical Trial of Pharmacological Ascorbate in Combination with
Chemoradiation in GBM-A phase 1 clinical trial was conducted at the University of Hospitals and Clinics to evaluate the safety of combining pharmacological ascorbate with standard radiation and temozolomide in glioblastoma (GBM) patients. Approval was sought, and obtained, from the University of Iowa Institutional Review Board (Biomedical IRB-01; IRB 201211713). This phase 1 study was registered with clinicaltrials.gov (NCT 01752491) prior to enrollment of the first subject. Newly diagnosed GBM patients referred for standard therapy (Stupp et al., 2005b) were invited to participate. Post-consent screening procedures included evaluating for glucose-6-phosphatase dehydrogenase deficiency as well as osmolarity tolerance by challenging the consented subjects with a 15 g ascorbate infusion.
The study was broken into two phases: radiation phase and adjuvant phase. Radiation phase was defined as the time period from day 1 of radiation through adjuvant cycle 1, day 1. Doses of pharmacologic ascorbate were escalated utilizing Storer's phase I clinical trial design BD (Storer, 1989) . Cohorts were defined as 15 g, 25 g, 50 g, 62.5 g, 75 g, 87.5 g, 100 g, and 125 g. Pharmacologic ascorbate was combined with sterile water for a targeted osmolarity of 500-900 mOsm L −1 . Ascorbate infusions were three times weekly, with maximum infusion rate of 500 mL hr −1 . Radiation (61.2 Gy in 34 fractions) and temozolomide (75 mg m −2 daily for a maximum of 49 days) similar to the treatment paradigm put forth by Stupp et al. (Stupp et al., 2005b ) ( Figure 7A ). After completing radiation, ascorbate infusions were reduced to twice weekly; dose remained unchanged from the radiation phase.
Adjuvant phase was defined as the time period from cycle 1 day 1 through cycle 6 day 28. During this phase, subjects underwent intrapatient escalation utilizing Simon's Accelerated Titration Design (Simon et al., 1997) . Prescribed doses utilized the same cohorts as the radiation phase. Subjects were dose-escalated after 2 infusions until a plasma level of 20 mM was achieved. Ascorbate infusions were performed twice weekly. Temozolomide was prescribed consistent with the Stupp regimen: 150 mg m −2 for days 1 through 5 of a 28 day cycle. A one-time dose escalation was allowed to 200 mg m −2 if cycle 1 was tolerated ( Figure 7A ). Subjects were evaluated for disease progression every 2 cycles utilizing the MacDonald criteria (Macdonald et al., 1990 ).
On a given day, during the radiation phase, GBM subjects received ascorbate infusions of 30 -180 min in duration (depending on the total dose) followed by radiation therapy. The dose escalation aspect of the study and the maximum infusion rate of ascorbate at 50 g hr −1 required this range of infusion times. The protocol did not specify when the radiation was to be administered relative to the infusion time, so for higher ascorbate doses, requiring longer infusion times (> 50 g), the subject received radiation therapy during the last hour of ascorbate infusion or immediately following infusion. Temozolomide chemotherapy was administered orally in the evening by the patient at home and the time between ascorbate infusion and temozolomide administration was not defined. This timing of ascorbate and temozolomide was continued throughout the adjuvant phase.
MGMT status was determined by a PCR-based analysis at ARUP National Reference Laboratory (Salt Lake City, UT). IDH subject status was determined immunohistochemically by the University of Iowa Hospitals and Clinics Clinical Histopathology Laboratory.
Dose limiting toxicities (DLTs) for the study included grade 4 infection, grade 3 nausea or vomiting despite maximum supportive care, grade 4 neutropenia or thrombocytopenia, and serious adverse events (SAE) with causality to the investigational agent. In addition to DLT, criteria for removal included progressive disease, patient's refusal to continue treatment, and extraordinary medical circumstances (e.g., the constraints of the protocol are considered detrimental to patient health).
All subjects agreed to, and participate in, lifelong follow-up for this study. Subject numbers are for convenience and are not representative of case ID numbers. Subjects 12 and 13 (Table S2) are included in the toxicity analysis (Tables S3, S4 ), but were not included in the progression free survival and overall survival analysis ( Figure 7A , 7C, 7D) because they received limited protocol-dictated therapy due to unrelated co-morbidities. Due to the small number of subjects in the longevity analysis we reported the average progression free survival (PFS) and overall survival (OS). The study included treating patients with 4 cycles of carboplatin AUC 6 and paclitaxel 200 mg m −2 every 21 days as first line chemotherapy combined with pharmacological ascorbate. Ascorbate was administered intravenously twice per week at a fixed dose of 75 g per infusion for 6 treatments per each 21 days cycle of chemotherapy. Pharmacologic ascorbate was combined with sterile water for a targeted osmolarity of 500-900 mOsm/L. Blood ascorbate levels and measures of reactive oxygen species were collected each cycle from subjects immediately prior to and after completing ascorbate infusions. On a given therapy day, chemotherapy infusions (paclitaxel followed by carboplatin) were initiated ~1 h following the completion of the ascorbate infusions.
So far, no grade 3/4 toxicities attributed to ascorbate have occurred. The regimen is well tolerated and no patients have withdrawn consent due to toxicities. We have not seen any unexpected or unusual increase in Grade 3/4 toxicities as compared to previously published literature, although it remains too early for a direct comparison. Responses to therapy were determined per RECIST 1.1 criteria (Eisenhauer et al., 2009) . Currently, a total of fourteen subjects are currently evaluable for response. Four of fourteen subjects have completed the trial with imaging-confirmed partial responses to therapy. Nine additional subjects demonstrated stable disease. Finally, one subject has progressed with the appearance of new lesions, although the target lesions are stable. All subjects agreed to, and participate in, lifelong follow-up for this study.
Quantification and Statistical Analysis
For all analyses, significance was determined at p < 0.05. *, **, or *** represent significance between exposure conditions. All analyses, unless specified elsewhere, were performed in GraphPad Prism ® (GraphPad Software, Inc.). Ascorbate toxicity curves ( Figure 1A , B) were generated using IGOR Pro version 6.36 (WaveMetrics, Inc.).
Where appropriate, figure legends define n and the definition of center and dispersion and precision measures. For analyses limited to two groups, Student's t-test was utilized. To study differences between three or more groups, one-way ANOVA analysis with Tukey's post hoc test was used. For all survival curves, the log-rank Mantel-Cox test was used. For NSCLC LIP curves ( Figure 6A ) and GBM/NHA toxicity curves ( Figure S1D ) non-linear regression curves were compared by the extra sum-of-squares F test. For GBM and NSCLCFt LIP curves ( Figure 6B , K) deviation from non-zero slope was determined from linear regression analyses. Box and whisker blot of patient plasma ascorbate concentrations ( Figure 7B ) are determined by the Tukey method The line and box represent the median value ± 25 th and 75 th percentiles or the interquartile range (IQR). Whiskers represent 1.5 times IQR. Any data points outside 1.5 times IQR are represented by individual dots.
Data are expressed as mean ± 1 S.E.M., unless otherwise specified. For each experiment, unless otherwise noted, n represents the number of individual biological replicates. For each biological replicate, n ≥ 3 technical replicates for all in vitro and ex vivo studies.
For GBM subject survival analyses, Subjects 12 and 13 (Table S2 ) are included in the toxicity analysis (Tables S3, S4 ), but were not included in the progression free survival and overall survival analysis ( Figures 7A, 7C , 7D) because they received limited protocoldictated therapy due to unrelated co-morbidities. significant differences between untreated control cells and any group denoted with a different symbol, at least p < 0.05. n.s. = not significant (p > 0.05). See also Figure S1 . treatment group. For all ex vivo studies, n ≥ 3 mice per group with n ≥ 3 technical replicates per sample. Data are represented as mean ± SEM. *represents significant difference, at least p < 0.05. μM FAS for 3 h prior to LIP quantification by flow cytometry or washed with PBS before exposure to ascorbate for 1 hr in fresh full media and then plated for clonogenic survival. For all in vitro studies, unless noted above, n ≥ 3 biological replicates with n ≥ 3 technical replicates per sample. Data are represented as mean ± SEM. *, ** represents significant differences between untreated control cells and any group denoted with a different symbol, at least p < 0.05. See also Figures S4, S5 . (A) Progression Free Survival (PFS) and Overall Survival (OS) of GBM subjects treated with pharmacological ascorbate, radiation and temozolomide. Subjects were treated with temozolomide daily with concurrent radiation therapy (radiation phase) for ~7 weeks followed by ~28 additional weeks of temozolomide therapy (adjuvant phases), for a total of ~35 weeks. The doses denoted adjacent to each subject number indicates the ascorbate dose received during the radiation phase dose-escalation study. All subject's doses were increased to achieve target plasma levels ≥ 20 mM during the adjuvant phase. Historical median PFS is 7 months and OS is 14.6 months. The green bars indicate the duration of active ascorbate therapy, blue bars indicate PFS, and red bars indicate OS. The vertical red lines indicate premature cessation of the clinical trial due to personal reasons; vertical light blue lines indicate Schoenfeld et al. Page 38
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